Mato, Anthony R

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 383

Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).

Schuster, S. J., Svoboda, J., Nasta, S., Chong, E. A., Porter, D. L., Landsburg, D. J., Mato, A. R., Bhoj, V. G., Milone, M., Lacey, S. F., et al. (2016) · Journal of Clinical Oncology

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 10